LONDON -- (Marketwire) -- 02/22/13 -- Stocks fell sharply for a second day in a row as some weak U.S. and Eurozone economic data, coupled with concerns over an early end to the Federal Reserve's bond buying program, weighed down sentiment. All three benchmark indexes fell sharply by mid-day trading on Thursday. At the end of Thursday's trading session, our research team took notice of a few stocks in the Drug Manufacturers-Major sector, Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Merck & Co. Inc. (NYSE: MRK). Wall Street Active research team has completed free research on PFE, JNJ and MRK. As a leading provider of free in depth reports and timely market updates, we invite you to sign up now at
Pfizer Shares End Lower
Share of pharmaceutical major Pfizer fell on Thursday, tracking losses in the broad market. The stock ended the day 0.58% lower at $27.41 on volume of 24.52 million. Despite yesterday's pullback, Pfizer's shares are still hovering around their 52-week high of $27.84. Year-to-date, the stock has gained more than 9%, outperforming the S&P 500. The stock is currently trading well above their 50-day and 200-day moving averages, which is a bullish signal. It has support at around $27. Sign up today and get useful insight about PFE for free at
Johnson & Johnson Finishes Marginally Higher
Despite the sharp decline in the broad market, Johnson & Johnson shares managed to post modest gains in Thursday's trading session. The stock finished the day 0.29% higher at $76.87 on volume of 9.47 million, which is close to the stock's daily average volume of 9.56 million. Yesterday, Johnson & Johnson shares rose to a 52-week high of $77.02. Year-to-date, the stock has gained nearly 10%. The stock has seen a series of highs since the start of 2013, which is a bullish signal. This bullish trend is further confirmed by the stock's MACD chart. The MACD is currently trading above the signal line and the zero-line. Free report on JNJ can be accessed by registering at
Merck & Co.'s Shares Up Nearly 4% this Year
Merck & Co shares have had a decent run this year, gaining more than 3.8%. On Thursday, the stock closed 0.38% lower at $42.50 on volume of 11.82 million. The stock had fallen sharply earlier this month; however, it rebounded after finding support at around $41. Merck's stock, this week, moved above its 50-day and 200-day moving averages, which suggests that market sentiment has once again turned bullish on the stock. This is confirmed by the MACD chart. The stock's MACD recently moved above the signal line, which is a strong bullish signal. Register with Wall Street Active and download the research on MRK for free at
Disclaimer: WSA Financial is not a registered investment advisor, and nothing in this release is intended as a solicitation to buy or sell any security. Our pro-traders only aim is to educate investors based on their experience, and to share their knowhow.
Ravi S. Kapur
Telecommunication, Information & Data Manager
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here